Cosentyx gains EU approval for new label extension 2nd March 2021 Novartis’ interleukin (IL)-17A inhibitor Cosentyx has gained an EU label update to include data for axial manifestations of psoriatic arthritis (PsA). In a statement, Novartis said that the label update makes Cosentyx (secukinumab) the first biologic with proven efficacy in all six key manifestations of PsA, and also the only biologic with ‘fast and lasting’ relief of axial manifestations of PsA in a dedicated trial. The label update includes data from the Phase IIIb MAXIMISE trial, which evaluated the efficacy and safety of Cosentyx in the management of axial manifestations of PsA.